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Abstract 
The SARS-CoV-2 virus is a member of the coronavirus family that caused the COVID-19 respiratory disease 
epidemic in China before the global pandemic of the disease in late 2019. The virus's genome is of 79% similarity to 
that of the SARS-CoV virus, using the ACE2 receptor to enter its target cells. The most common symptoms of this 
disease include fever, cough, pulmonary involvement, and sometimes gastrointestinal symptoms. A decline in both 
the number and function of lymphocytes and a severe increase in leukocyte inflammatory activity are among the most 
obvious immunological complications of this disease. If the immune system response to the virus is inadequate, the 
disease can become acute. Immune cells activity leads to a sharp increase in the number of blood cytokines, causing 
"cytokine storm," which in turn can cause systematic damages to the heart, lungs, and kidneys, and ultimately may 
lead to death. Mesenchymal stem cell therapy offers a promising approach to reducing the destructive impacts of 
infection in patients with COVID-19. Mesenchymal stem cells can secrete immune-modulating factors that suppress 
cytokine storms. Furthermore, the role of mesenchymal stem cells in preventing cell death and inhibiting tissue 
fibrosis has been well demonstrated. This review shows available clinical trials that have tapped into the therapeutic 
potential of the umbilical cord mesenchymal stem cells in patients with COVID-19. 
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Introduction 
In late December 2019, a case of unidentified 
pneumonia was reported in Wuhan City (Hubei 
Province, China) whose clinical manifestations were 
similar to those of viral pneumonia. While the World 
Health Organization (WHO) named the virus 
“COVID-19”, the International Committee on 
Taxonomy of Viruses (ICTV) called it “SARS-CoV-
2”. This virus belongs to the β coronavirus family, 
which is prevalent in the environment and, like other 
viruses, has many potential natural hosts that can act 
as either intermediate or ultimate hosts (1, 2). 
Coated with a single-stranded ribonucleic acid 
(RNA) genome, this virus uses a cellular receptor 
called angiotensin-converting enzyme (ACE2) to 
enter the target cells. In addition to multiplying in the 
upper respiratory tract efficiently, this coronavirus 
also tends to multiply in the cells located in the lower 
respiratory tract. As a result, lesions in the lower 
respiratory tract are bound to occur. Approximately 
81% of the patients diagnosed with Covid-19 show 
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mild symptoms, and in 14% of the cases, the patient 
manifests severe symptoms, including pneumonia 
and shortness of breath. Moreover, in 5% of the 
cases, the patient condition worsens, which is 
associated with respiratory failure, Septic shock, and 
failure in other body organs (3). Due to the novelty 
of this virus amid human populations, new reports 
are being published daily regarding various aspects 
of its pathogenicity. Symptoms such as fever, cough, 
fatigue, muscle aches, joint pain, and shortness of 
breath have been reported as common clinically 
confirmed symptoms of the virus (3–6). 
Extensive lung damage detectable in patients with 
MERS, Covid-19, and SARS infections leads to 
Acute Respiratory Distress Syndrome (ARDS) in 
some patients. Alterations in the balance of immune 
cells and uncontrolled production of various 
cytokines are the main causes of ARDS (7). 
Immunopathological studies have proved that the 
role of the acute inflammatory responses in cases of 
severe infections with respiratory viruses is 
associated with a high mortality rate. The migration 
of various types of innate immune cells into the 
respiratory tract triggers the cytokine storm process_ 
which is referred to as life-threatening, maximizing 
the severe immune system responses in the lungs (8). 
Recent studies have shown that macrophages, 
neutrophils, dendritic cells, innate immune receptors, 
and cytokines have a key role in lung tissue damage. 
Macrophages accumulate in lung tissue, producing 
proinflammatory cytokines that reduce the virus 
titers in the lung tissue. However, various studies 
have shown that following the infection with 
respiratory viruses, CCR2-expressing monocytes 
can play a destructive role and cause lung tissue 
damage (9,10). These cells are the principal source 
of TNF-α production in the infected lungs and 
therefore considered one of the major factors in the 
immunopathogenesis of disease and thus mortality 
rate. Even at low virus titers, their products hinder 
the recovery of pneumonia and can lead to death 
(11). Thus, what is vital in the pathogenesis of this 
disease is the immune system's response against the 
virus. 
Stem cell-based therapies, particularly mesenchymal 
stem cells (MSCs), have been shown to have 
excellent potential to treat many diseases (12,13). 
MSCs have the function of regulating the immune 
system, known as immunomodulatory function, and 
affect both the innate and acquired immune system. 
A unique feature of these cells is their ability to 
suppress and moderate immune responses. MSCs 
have an inhibitory impact on various immune system 
cells such as T lymphocytes, B lymphocytes, natural 
killer cells (NK), and dendritic cells, thereby 
reducing and regulating immune responses (14). 
Furthermore, MSCs reduce the expression of MHC-
II, CD11c, CD83, and co-stimulation molecules on 
monocytes (15), thereby decreasing pro-
inflammatory cytokines_ TNF-α and IL-12 (16,17).  
In contrast, they increase the production of anti-
inflammatory cytokines such as IL-10 on monocytes, 
which indicates the ability of these cells to inhibit 
dendritic cells. Besides, MSCs have a major impact 
on the innate immune system, particularly inhibiting 
natural killer cells. They exert their inhibitory 
function on NK cells via reducing the expression of 
NKG2D, NKP44, and NKP30 receptors on the 
surface of these cells. They also inhibit IFN-Y 
production. Consequently, the proliferation of NK 
cells is ultimately hindered (18,19). 
The principal source of mesenchymal stem cells in 
the bone marrow, from which the cells are isolated 
and cultured. Yet, mesenchymal cells have recently 
been isolated from other sub-sources_ adipose tissue, 
placental tissue, peripheral blood, connective tissue, 
and skeletal muscle. These sources are far more 
accessible than bone marrow, and thus, 
mesenchymal cells are isolated with ease (20). 
Therefore, due to the ability of MSCs to secrete anti-
inflammatory, anti-fibrosis, and anti-apoptotic 
cytokines, these cells have been used to treat ARDS, 
which ultimately reduces the cytokine storm (21,22). 
This review article demonstrates the therapeutic 
potential of mesenchymal stem cells to modulate the 
immune system and available clinical trials that have 
used the therapeutic potential of umbilical cord 
mesenchymal stem cells in Patients with COVID-19. 
 
COVID-19 diagnosis and immunopathology 
Immunopathology 
COVID-19 is a positive-strand RNA virus that can 
target both humans and animals (23). Patients with 
chronic respiratory and cardiac diseases, diabetes, 
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and malignancies are deemed high-risk groups (24). 
Fever, cough, fatigue, and myalgia are the most 
common symptoms in confirmed COVID-19 cases 
(25). SARS-COV-2 enters cells through the 
interaction of its spike (S) protein with angiotensin-
converting enzyme-2 (ACE-2) after its activation by 
TMPRSS2 or furin proteases. ACE-2 and TMPRSS2 
are markedly expressed on the heart, brain, and 
kidney (26).  
COVID-19 has two major clinical phases. The first 
phase identifies with infecting target cells, causing 
severe clinical symptoms like pulmonary damage, 
and the so-called “cytokine storm” is the second 
phase identified by overexpression of several genes 
such as NF-kB, STAT-3, IL-6, IL-8, G-CSF (27). 
When the virus commences replication, even with a 
very low viral load, the inflammatory response 
rapidly expands, leading to organ failure (Fig1). 
Increased levels of IL1B, IL6, IFNᵧ, and MCP1 in the 
blood of patients with severe lung damages highly 
suggest that cytokine storm has pertained to the 
severity of the disease (26). Whereas it appears that 
young patients have a balanced concentration of 
proinflammatory and anti-inflammatory cytokines, it 
is not the case for elderly patients. A balanced 




Up to now, Real-time reverse transcription-
polymerase chain reaction (RT-PCR) is the most 
sensitive and specific method for the diagnosis of 
covid-19 (29). Nonetheless, this method is costly, 
time-consuming, and has a 20% false-negative rate 
(30). The study of Wenling Wang et al. defined the 
most sensitive sample as Bronchoalveolar lavage 
(93% sensitivity), and in the case of SARS-Cov-2 
detection, by RT-PCR, the most common targets are 
the ORF1ab/RdRp, E, N, and S genes (29). 
 
CT scan 
A diagnosis and treatment protocol published by the 
National Health Commission of China shows there 
are four severity levels for COVID-19 based on 
clinical manifestation:  mild, moderate, severe, and 
critical disease. Respiratory factors, including 
oxygen saturation and progression in pulmonary 
imaging, are some criteria for classification (31). A 
study on acute lung injury of COVID-19 cases 
reported three diagnostic hallmarks_ persistent viral 
infection, dysfunction of endothelial, and presence of 
abnormal pneumocystis and syncytial giant cells. 
Moreover, some researchers have reported atypical 




Serological tests measure host humoral immune 
response and can detect both waning and previous 
infection, thus they are a monitoring system for 
COVID-19 pandemic. these tests, however, cannot 
determine whether individuals are resistant or not 
(25). Tests based on antibodies (IgM and IgG ) are 
of low sensitivity and specificity, but they are better 
means of screening than CT scans in the sense that 
the radiation is detrimental to health, and the costs 
are comparatively high (30). Rapid antigen detection 
(RAD) tests (the select method of this study) can 
detect COVID-19 antigen by immobilized coated 
SARS-COV-2 antibody (32). 
 
Laboratory findings  
The complete blood count (CBC) is a quick, 
inexpensive test that provides beneficial 
information_ count of WBCs, platelets, 
lymphocytes, as well as NLR (Neutrophil-to-
Lymphocyte ratio), and PLR (Platelet-to-
lymphocyte ratio) (33). In addition to decreased 
amounts of FDP, a significant decline in fibrinogen 
and antithrombin levels has recently been reported in 
non-survivor hospitalized patients. C-reactive 
protein is an acute-phase protein that increases in 75-
93% of patients with severe COVID-19. Elevation of 
LDH enzyme is common in Patients with COVID-
19, particularly patients in the ICU setting, indicating 
an unfavorable outcome. Lymphopenia (defined as 
an absolute count <10 × ten 9/L) is deemed an 
informative index in Patients with COVID-19. 
However, it is less prevalent in children (34). Several 
Interleukins, including IL-1β, IL-6, IL-2, IL-10, and 
TNFα have been shown to increase in the patients 
with severe COVID-19. Furthermore, some studies 
have shown that the increased D-dimer levels, as 
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well as decreased PLT counts, are highly linked with 
severe conditions and high mortality rates.  
(31). 
 
Treatment of COVID-19 
Since, at this time, there are no approved treatments 
for COVID-19, prevention is considered crucial. 
However, some attributes of this virus such as non-
specific features of the disease, the infectivity, 
transmission from even asymptomatic individuals, 
and long incubation period, make prevention 
somewhat arduous (35). 
 
Drugs 
Of all drugs, treatments are somewhat confined to 
Hydroxychloroquine. Hydroxychloroquine is an 
antimalarial drug whose antiviral impacts against 
COVID-19 have been shown. Its direct antiviral 
activity lies in increasing intracellular pH. Other 
mechanisms are the immune-modulating effect 
through inhibition of toll-like receptors signaling, 
decreasing inflammatory cytokines, and anti-
thrombotic effects (36). It also functions as a novel 
class of autophagy inhibitors (37). Some drugs are 
available to control the proinflammatory cytokines, 
including “Inhibitor of Janus kinases” (i.e., 
Ruxolitinib), and “Monoclonal antibodies” (i.e., 
Tocilizumab). Tocilizumab is an anti-IL-6 
monoclonal antibody binding to both soluble and 
membrane receptors of IL-6 (38). One of the possible 
anti-inflammatory tactics is “microRNA targeting” 
since microRNAs are deeply involved in the 
expression of cytokines (27). 
 
CCP 
Due to the prior success of convalescent plasma (CP) 
against RNA viruses, it appears sensible to utilize it 
against COVID-19. In addition to neutralizing the 
pathogen, CP can create passive immunomodulatory 
attributes. Thus, the World Health Organization 
(WHO) and the United States Food and Drug 
Administration (FDA) published informative 
guidelines as to how COVID CP (CCP) could be 
efficiently used and who the appropriate donors are. 
A new study demonstrated that CCP significantly 
improved oxygen saturation, elevated lymphocyte 




There are various vaccine platforms: protein-based, 
live attenuated, inactivated virus, and novel gene-
based vaccines (GBVs) tactics such as nucleic acid 
and viral vector (40). The conserved regions are 
considered appropriate targets for neutralizing 
antibodies in the sense that they do not alter 
significantly over time, and thus this strategy could 
be useful for the development of a universal vaccine 
(38). 
 
Mesenchymal stem cell-based therapies for 
inflammatory mediated disorders 
MSCs are being studied as a promising and attractive 
cell-based treatment alternative to inflammatory 
disorders due to their immunomodulatory functions. 
Several clinical trials on MSC-based products are 
currently being conducted. The immunosuppressive 
properties of MSCs lie in the release of 
immunoregulatory molecules and cell-to-cell 
contact. MSCs can prevent the proliferation as well 
as the function of T cells, dendritic cells, B cells, and 
natural killer cells. They can also increase the 
proliferation of Treg cells. Furthermore, it has been 
shown that the immunomodulatory activities and 
viabilities of MSCs may increase by genetic 
modifications, preconditioning, and 3D-cultured 
systems. Nevertheless, due to the different problems 
clinical applications are somewhat restricted (41).  
Considerable advances have been made in 
understanding the anti-inflammatory and 
immunomodulatory basic mechanisms of MSCs. In 
Vitro, studies have shown that MSCs may respond in 
opposite directions depending on the intensity of 
environmental signals. For example, they appear to 
promote inflammation when the immune system is 
suppressed and vice versa (42). In the primary stages 
of inflammation, MSCs activate pro-inflammatory 
signals through IL-1β and Toll-like receptors, tumor 
necrosis factor (TNF-α), and interferon (IFN-γ); 
hence, inflammation. These stem cells also boost T-
cell activation by secreting some chemokines, 
including macrophage inflammatory protein-1, C-X-
C motif ligand (CXCL9), CCL5, and CXCL10, 
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thereby recruiting more lymphocytes. In this stage, 
low levels of inflammatory signals such as TNF-α 
and IFN-γ, are enough to upregulate chemokine 
secretion, but not to induce a remarkable expression 
of immunomodulatory mediators (43). 
In the final stages, high levels of pro-inflammatory 
factors_ IL-1β, IFN-γ, and TNF-α_ stimulates MSCs 
to reduce inflammation and prevents autoimmune 
reactions by releasing TGF-β, IL-10, IDO, or iNOS. 
Eventually, it leads to puberty, antigen presentation 
to DC and T cells, proliferation, and also inhibition 
of migration (44,45). Thus, the switch between the 
anti-inflammatory and pro-inflammatory states 
occurs by IDO or iNOS interventions (Fig2) (46). 
Furthermore, it has been shown that, in in vitro 
conditions, MSCs can initiate immunosuppressive 
activities on activated B cells. They reduce B cell 
proliferation by stopping the cell cycle, affecting B 
cell differentiation. In addition, MSCs decrease the 
production of immunoglobulin IgM, IgA, and IgG 
(47). 
Many studies have proved that MSCs have a major 
role in inducing regulatory B cells. Inflammation is 
eliminated by regulatory CD23+/CD43+ B cells 
treated with MSCs, for example (48,49). More recent 
evidence shows that human umbilical cord-derived 
MSCs, via CD5+ regulatory B cells, creates a 
defensive mechanism against colitis (50). In 
addition, MSCs suppress inflammation processes in 
various ways_ the down-regulation of pro-
inflammatory factors, the up-regulation of anti-
inflammatory factors, and perhaps direct cell contact 
suppression through immune reactions (51).  
During lung injury, an unsuitable immune response 
or inappropriate repair process often results in 
irreversible lung tissue damage, causing fibrosis 
development followed by lung tissue malfunction. 
Anti-inflammatory drugs and inhaled corticosteroids 
appear highly efficient in patients with inflammatory 
lung disorders, but their long-term use is associated 
with severe side effects. Therefore, novel therapies 
that promote the regeneration of damaged alveolar 
epithelial cells as well as reduce inflammation are 
vital. MSCs can modulate the proliferation, 
activation, and effector function of each immune cell 
that plays a pivotal role in the pathogenesis of acute 
and chronic inflammatory lung diseases. Thus, to 
suppress lung-infiltrated immune cells, MSCs have 
the potential to change into alveolar epithelial cells 
in vitro and, therefore, represent new players in cell-
based therapy for inflammatory lung disorders (52). 
 
Clinical applications of umbilical cord 
mesenchymal stem cells for COVID-19 treatment 
A guideline recently published by The Italian 
College of Anesthesia, Analgesia, Resuscitation and 
Intensive Care demonstrates the promising role of 
stem cells in treatment and early discharge of 
coronavirus patients, with a decreased number of 
hospitalized patients in intensive care units as a result 
of faster recovery (53). Thus, pharmacologic and 
supportive therapies aside, UC-MSCs seem to be the 
most potent strategy for COVID-19 treatment. 
A good number of studies have been conducted into 
investigating the effectiveness of umbilical cord 
mesenchymal stem cells in COVID-19 cases. By 
way of illustration, findings of the research have 
demonstrated that Immunity-and-matrix-regulatory 
cells extracted from human embryonic stem cells 
have therapeutic impacts on mice with lung injury 
and fibrosis_ without any side effects. Because 
Immunity- and matrix-regulatory cells (IMRCs) 
have shown promising effectiveness without any 
side effects, they seem more beneficial, for the 
treatment of mice and monkeys, than both UCMSCs 
and the FDA-approved “pirfenidone” (54). Studies 
that have evaluated the efficacy of umbilical cord 
mesenchymal stem cells in Patients with COVID-19 
are summarized in table 1. 
In an experimental study (55), researchers randomly 
divided 41 severe Patients with COVID-19 into two 
groups: the standard treatment group and the 
standard treatment plus hUC-MSC infusion group. 
To assess the effectiveness of UC-MSCs for the 
treatment of severe COVID-19, researchers 
measured several items in both groups _ the 
incidence of progression from severe to a critical 
stage, mortality within 28 days, clinical symptoms 
improvement, the required time for clinical 
symptoms improvement, imaging, hematologic 
indicators, including C-reactive protein, lymphocyte 
count, and interleukin 6. The results showed that in 
the treatment group, no one neither turned into 
critical condition nor died, while in the control 
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group, the condition for 4 participants aggravated to 
the critical one so that they received invasive 
ventilation, 3 of whom passed away, and the 28-day 
mortality rate was 10.34%. Moreover, it took a long 
time for clinical manifestations to improve in the 
control group in comparison with the hUC-MSC 
treatment group. The improvement of some indices 
such as weakness and fatigue, shortness of breath, 
and low oxygen saturation was remarkable on the 
third and 7th days of stem cell infusion. Besides, 
from day 3 of infusion, CRP and IL-6 levels were 
significantly lower, the time for the lymphocyte 
count to return to normal was noticeably faster, and 
the uptake of lung inflammation, based on CT 
imaging, was considerably shorter in the hUC-MSC 
group than in the control group. Altogether, 
intravenous transplantation of hUC-MSCs seemed to 
be a safe and effective choice for treatment and 
saving the lives of Patients with COVID-19. 
In a pilot study, 16 severe and critically severe 
COVID-19 pneumonia patients were recruited in a 
single-arm trial to receive transplantation of UC-
MSCs during four rounds. The intervention lasts for 
four weeks, and at the end of the first, second, and 
fourth week following data were obtained: 
oxygenation index, inflammatory biomarkers, 
radiological presentations of the disease, and 
lymphocyte subsets count. In addition, any adverse 
event was recorded from the inception of the study. 
The findings indicated that oxygenation index, the 
radiological presentations (ground-glass opacity), as 
well as lymphocyte count and lymphocyte subsets 
(CD4+ T cells, CD8+ T cells, and NK cells), count 
ameliorated after the transplantation. No infusion-
related or allergic reactions were reported during the 
study. The mortality rate of participants was 
considerably lower than historical mortality rates 
(6.25% and 45.4%, respectively). The above-
mentioned findings showed that patients with severe 
and critically severe COVID-19 pneumonia might 
benefit from intravenous transplantation of UC-
MSCs as a safe and feasible intervention (56).  
At Taikang Tongji Hospital in Wuhan, China, 
physicians treated 31 severe Patients with COVID-
19 with pneumonia using UC-MSCs. They found out 
UC-MSC can revitalize oxygenation and inhibit 
cytokine storm via down-regulatory effect (57), 
which was consistent with previous studies. Similar 
to UC-MSCs, bone marrow MSC can successfully 
inhibit cytokine storms and result in tissue repair and 
regeneration as well as hypoxia improvement, 
immune reconstitution, and cytokine storm 
inhibition (46,47). 
In a phase 1/2a double-blind, randomized controlled 
trial, 24 COVID-19 ARDS patients were enrolled. 
ARDS severity was the basis of randomization, and 
the study was performed with the intent of designing 
a treat. In the UC-MSC treatment group, participants 
received 100 ± 20 × 10 UC-MSCs on days 0 and 3. 
In the control group with equal samples, two 
infusions of vehicle solution were administrated. 
Results offered those infusions of UC-MSC might 
benefit Patients with COVID-19 suffering from 
ARDS. Significant reduction in Inflammatory 
cytokines on day 6, considerable improvement in 
patient survival (91% vs 42%, P = .015), SAE-free 
survival (P = .008), and time to recovery (P = .03) 
were observed in UC-MSC treatment group. 
Therefore, researchers concluded UC-MSC infusion 
is a safe and beneficial treatment for ARDS 
consequent to COVID-19. 
In another study, researchers infused allogeneic 
human umbilical cord mesenchymal stem cells (UC-
MSCs) to a critically ill male patient and monitored 
the treatment process as well as outcomes to decide 
whether UC-MSCs is an adjuvant treatment for 
COVID-19 or not. The patient was referred to the 
hospital, complaining of fever, cough, sputum, 
dyspnea, poor appetite, poor mental state, and 
fatigue. In the first days of admission, he was not 
diagnosed with COVID-19, and thus routine 
treatment for bacterial pneumonia was 
administrated. On February 3, the result of the 
nucleic acid test indicated that he had been infected 
with SARS-nCov-2019. The medical team decided 
to commence UC-MSCs transfusion. They 
monitored the patient for 14 days. On February 9, the 
SpO2 raised and reached 95%. 4 days later, the 
patient could independently breathe without a 
ventilator, and his O2 saturation remained within the 
normal range. On February 4, severe fibrosis in both 
lungs was observed via a CT scan. One week after 
UC-MSCs transfusion, infiltration decreased 
considerably and the absolute lymphocyte count was 
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unfavorable. Absolute Lymphocyte Count markedly 
increased following adjuvant UC-MSC therapy. It is 
hypothesized that UC-MSCs may have changed the 
immune system function, enhancing inflammatory 
reaction, the lung, and multiple organ functions, and 
as a result, critically ill patient's condition was 
improved. Based on these results, UC-MSC 
transfusion appears to be a novel treatment for 
patients suffering from COVID-19. However, more 
evidence-based practices are required to support the 
effectiveness of this method (58). 
Laiang et al. monitored a patient complaining of 
fatigue, white foaming sputum, and fever with a 
body temperature of 38.2° (59). Being a passenger 
on a flight from Wuhan_ on January 21, 2020_ she 
was instantly referred to the nearby hospital, and the 
result of the real-time PCR showed she was infected 
with SARS-CoV-2. On day 11 (February 9), 
following severe injuries observed in the body 
organs, secondary to the inflammatory response and 
side effects, the medical team decided to begin 
hUCMSCs adoptive transfer therapy. After the first 
transfusion of hUCMSCs, the patient tolerated the 
treatment so well that no adverse effect was reported. 
Serum bilirubin, CRP, ALT, and AST concentrations 
steadily decreased_ inconsistent with improvement 
in several other vital signs. On the 17th day, the 
patient could breathe without a trachea cannula, and 
was able to stand by herself. The second transfusion 
returned the white blood cell and neutrophil counts 
to the normal range. After the transfusion of 
UCMSCs, clinical manifestations and indices like 
CD3+ T cell, CD4+ T cell, and CD8+ T cell 
ameliorated (60). Because MSCs can modulate 
immune responses, repair tissues, down-regulate 
pro-inflammatory cytokines and inhibit 
inflammation, it has the potential to be a beneficial 
treatment for Patients with COVID-19. 
 
Therapeutic potential of UC-MSCs-derived 
exosomes in COVID-19 
UC-MSCs-exosomes are an increasingly potential 
candidate for the treatment of ARDS and COVID-
19. However, there have been few studies on the use 
of UC-MSCs-exosomes in the treatment of COVID-
19. Preclinical studies have provided favorable 
therapeutic benefits for the exosomes derived from 
other sources of MSCs (61). Nevertheless, 
considering the source of MSCs, some controversial 
issues emerge as follow the donor and source; the 
dosage, the route of injection and the repetition 
number; the age of cells (young cells or 
cryopreserved cells); primary cells or expanded 
passages. In addition, the exosomes themselves are 
subject to controversy based on their bioactive 
constituents, capacity, mechanisms of interaction 
with the inflammatory immune cells and stromal 
cells in the damaged lung microenvironment. 
Large-scale generation of UC-MSCs-exosomes 
needs many MSC cells and a massive culture 
medium, which is expensive. Therefore, further 
studies on biological facets of the UC-MSCs-
exosomes would help alleviate the harmful effects of 
COVID-19 pandemic (62). 
 
Challenges to use UC-MSCs 
Clinical observations indicate the high potential of 
UC-MSCs in the treatment of disease COVID-19 
disease. However, there are still some issues 
associated with the administration of MSCs. 
Methods of preparation, the number of MSCs, and 
the age of the cell population can surely lead to 
several functional differences. This variety might lie 
in the potential of cytokine liberation, cytokine 
content, and therapeutic ability. Even the difference 
in size, shape, and passage number of UC-MSCs or 
MSC-EVs may additionally lead to complex curative 
effects of this biological substrate. The expense and 
immediacy of sample preparation are also subjects 
that should be taken into consideration. 
Nevertheless, MSC-EVs seem to be much more 
affordable and more comfortable in large-scale 
production than their cells of origin (63).  
Another principal challenge to using UC-MSCs 
therapy for COVID-19 cases is that COVID-19-
infected patients are at the risk of hypercoagulation. 
In addition, MSCs have been shown to possess pro 
coagulation characteristics. Therefore, attention to 
nonintravascular administration routes for MSC or 
MSC-EV is encouraged to diminish the risk of 
COVID-19 cell therapy and increase the safety and 
efficacy of this type of therapy (64).
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Table 1. Details of UC-MSC therapy and outcomes. 
First Author Country 
Study 
Design 
Details of UC-MSC Therapy Outcome 
Zhu et al. (58) China 
Case 
Report 
Before the intravenous drip, UC-MSCs were 
suspended in 100 mL of normal saline, and the 
dosage was calculated by 1 × 106 cells per 
kilogram of wedight. The injection was 
performed within one hour, with an average 
speed of ~25 drops per minute. Antibiotic 
administration was terminated on the day UC-
MSC was administered, and the rest of the 
treatment remained unchanged. 
ALT, AST, BUN, CRP↓, the 
absolute number of lymphocytes, 
NK cells ↑ 





Before the intravenous drip, UC-MSCs were 
suspended in 50 mL of normal saline, and the 
total number of transplanted cells was 1 × 108 
cells once. The patients were administered 4 
times in total, with one-day intervals in between. 
The transplantation was performed within 1.5 
hours with a speed of 30-60 drops per minute. 
CD4+ T cells, CD8+ T cells, NK 
cells ↑, IL-2, IL-4, IL-6, IL-10, 
TNF-α, IFN-γ, CRP, PCT ↓ 
Shu et al. (55) China 
Clinical 
trial 
Intravenous administration was used. Before the 
intravenous drip, the MSCs were suspended in 
100 ml of normal saline and the total number of 
transplanted cells was calculated as 2 × 106 
cells/kg. The infusion was into the patients’ right 
cubital veins and lasted approximately 1 h (35 
drops/min). 
C-reactive Protein, IL-6 ↓, 
Lymphocyte number, oxygenation 
index ↑, Chest CT scans indicated 
that CT scores, the number of lobes 
involved, GGO, and consolidation 
was improved. 







Subjects in the UC-MSC treatment group 
received two intravenous infusions of 100 ± 20 
× 106 UC-MSCs each, in a 50 mL vehicle 
solution containing human serum albumin and 
heparin, infused over 10 ± 5 minutes, on days 0 
and 3. Subjects in the control group (n = 12) 
received two infusions of 50 mL vehicle 
solution, on day 0 and day 3. Best standard care 
was provided for both groups regarding the 
current institutional COVID-19 guidelines. 
IFNg, IL-6, and TNFa cytokines 
and RANTES chemokine. GM-
CSF and PDGF-BB ↓ (only in the 
UC-MSC treatment group), SAE-
free survival, time to recovery↓, 
patient survival↑ 





UC-MSCs (1 × 106 cells per kilogram of weight) 
were suspended in 100 ml normal saline and 
transfused during three steps according to the 
patients’ condition. 
Lymphocyte count, PaO2/FiO2↑, 
Interleukin-6, Procalcitonin, C-
reactive protein, White blood cell 
count, D-dimer ↓ 





The allogenic hUCMSCs were administrated 
intravenously 3 times (5*107 cells each time) on 
days 13, 16, and 19. During the treatment, 
antibiotics were given to prevent infection. 
thymosin α1 was also given. 
counts of CD3+T cell, CD4+ T cell, 
and CD8+ T cell ↑, neutrophil-to-
lymphocyte ratio, D-dimer, serum 
bilirubin, white blood cell count, 
neutrophil count, CRP, ALT, and 
AST (after the second 
administration) ↓, pulmonary 
inflammatory reaction: 
ameliorated (based on chest CT 
images) 
PCT: procalcitonin; AST: aspartate aminotransferase; ALT: alanine transaminase; BUN: blood urea nitrogen; NK: natural 
killer cells; GGO: Ground-glass opacity; GM-CSF: granulocyte-macrophage colony-stimulating factor; PDGF: platelet-
derived growth factor; RANTES: regulated on activation, normal T cell expressed and secreted; IL: interleukin; SAE: serious 
adverse events; IFNg: Interferon gamma; UC-MSCs: umbilical cord mesenchymal stem cells; PaO2/FiO2 ratio: ratio of the 
partial pressure of arterial oxygen to the percentage of inspired oxygen. 
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Figure 1. Angiotensin-converting enzyme 2 receptor is expressed on respiratory epithelial cells and endothelial cells. 
SARS-CoV-2 enters cells via binding to this enzyme. Viral replication disturbs inflammation and coagulation, 
eventually resulting in multiple organ failures. 
 
 
Figure 2. Histological evaluation of liver sections of normal rats treated with saline (control) or 700mg/kg of N-
acetylcysteine (NAC), stained with Masson's Trichrome technique. 100x magnification of the liver sections showing the 
lobular central veins, the portal spaces, the normal sinusoidal radial branches, and the normal structure of the liver in 
both control and NAC groups. The portal space histology in control group indicated the presence of a small connective 
tissue and a very small number of mononuclear cells. Minimum connective tissue without any infiltration observed in 
the portal triad of NAC group. The lobular central vein of control and NAC groups indicating normal structure with 
normal sinusoidal space, without any signs of fibrosis.
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Conclusion 
COVID-19 disease is a global crisis, especially for 
healthcare workers, with a broad range of adverse 
effects which involve chronically ill patients who are 
non-responsive and unable to benefit from traditional 
therapies. Owing to the evidence obtained from 
preclinical and preliminary studies, UCS-MCS has 
anti-inflammatory and immunomodulatory 
functions, and thus, it can improve the recovery time 
as well as damaged tissues (53). Previous studies 
have suggested that the primary organ invaded by 
coronavirus is the lung, thus administering UCS-
MCS into the lung may be beneficial to patients. In 
conclusion, it seems that UCS-MCS therapy, as an 
almost cost-effective and non-invasive intervention, 
might enhance the treatment of critically ill Patients 
with COVID-19. 
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